Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FM-VP4 in primary hypercholesterolemia
NCT00293878Phase 2Completed
- Sponsor
- Forbes Medi-Tech Inc.
- Start
- Nov 2005
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of disodium ascorbyl phytostanol phosphate in hypercholesterolemia, sponsored by Forbes Medi-Tech Inc. Primary endpoint: Low-Density Lipoprotein Cholesterol at 12 weeks. Started Nov 2005; status: completed.
02
Drugs
disodium ascorbyl phytostanol phosphate
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00293878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293878.